Category Archives: 2018

New Prostate Cancer Screening Recommendations for Men Aged 55-69.

In early May, the United States Preventive Services Task Force (USPSTF) finalized its new prostate cancer screening recommendation, which upgrades its recommendation for men 55 – 69 years old to a C rating. While the updated rating is a step more »

Posted in 2018, Diagnostics, Genetics, Imaging | Leave a comment

Waiting, Submitting and Trusting – an Often-Needed Message

We who struggle with various medical conditions are often either seeking guidance from God about specific decisions or awaiting results and answers to our prayers. In Psalm 130, the author writes about being in deep distress facing a situation that more »

Posted in 2018, Encouragement | Leave a comment

PARP Inhibitors and Prostate Cancer- Keeping Cancer Cells From Repairing Themselves

Drugs targeting poly (ADP-ribose) polymerase (PARP) are helping patients battle back more effectively against cancer. An enzyme, PARP helps repair damaged DNA in cells, and while that’s a good thing in healthy people, it can be bad news for cancer patients. To more »

Posted in 2018, Diagnostics, Genetics, Imaging, Treatment Information | Leave a comment

A Prostate Cancer Toolkit for Newly Diagnosed Men and Their Families.

Zero-the Project to End Prostate Cancer recently published an e mail manual for men newly diagnosed with prostate cancer and for their families. It can be found at the following link.  Topics include prostate cancer basics, methods used in its more »

Posted in 2018, General Patient Information | Leave a comment

Zytiga (Abiraterone) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

On February 8th, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga® (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk more »

Posted in 2018, Treatment Information | Leave a comment

Big Anxieties, Little Faith

As part of the Sermon on the Mount, Jesus spoke the following words from Matthew 6:25-30 about worry and anxiety, emotions and feelings most of us with prostate cancer can relate to. “Do not be anxious for your own life, more »

Posted in 2018, Encouragement | Leave a comment

Apalutamide (ARN-509) Approved to Treat Non-Metastatic, Hormone-Resistant Prostate Cancer

On Feb. 14th, the U.S. Food and Drug Administration approved apalutamide (Erleada®, previously  called ARN-509) for the treatment of non-metastatic, castration (hormone)-resistant prostate cancer (CRPC). Apalutamide could be administered in a clinical setting wherein men who are being treated with more »

Posted in 2018, Treatment Information | Leave a comment

A Phase 3 Trial Shows that Xtandi Reduces the Risk of Metastasis in Hormone-Resistant Prostate Cancer

According to results just recently presented at the February 2018 Genitourinary Cancers Symposium in San Francisco, treatment with Xtandi® (enzalutamide) reduced the risk of metastasis or death in hormone-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond more »

Posted in 2018, Treatment Information | Leave a comment

Positive Early-Stage Study Results of ProstaVax, Another Prostate Cancer Vaccine.

OncBioMune’s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines — molecules produced by more »

Posted in 2018, Treatment Information, Uncategorized | Leave a comment

Prostate Cancer Drugs Currently Approved or in Late-stage Clinical Trials.

At the time of this writing, there are thirteen (14) drugs currently approved by the Food and Drug Administration for the treatment of prostate cancer. There are others which are in various stages of clinical development or review.  A number of more »

Posted in 2018, Treatment Information | 1 Comment